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Differentiation of human adipose-derived
stem cells into neuron/motoneuron-like
cells for cell replacement therapy of spinal
cord injury
Shane Gao1, Xuanxuan Guo1, Simeng Zhao2, Yinpeng Jin3, Fei Zhou4, Ping Yuan5, Limei Cao6, Jian Wang1, Yue Qiu1,
Chenxi Sun1, Zhanrong Kang7, Fengjuan Gao8, Wei Xu5, Xiao Hu5, Danjing Yang1, Ying Qin1, Ke Ning 9,
Pamela J. Shaw9, Guisheng Zhong2, Liming Cheng5, Hongwen Zhu10,11, Zhengliang Gao 12, Xu Chen6 and Jun Xu1
Abstract
Human adipose-derived stem cells (hADSCs) are increasingly presumed to be a prospective stem cell source for cell
replacement therapy in various degenerative and/or traumatic diseases. The potential of trans-differentiating hADSCs
into motor neuron cells indisputably provides an alternative way for spinal cord injury (SCI) treatment. In the present
study, a stepwise and efﬁcient hADSC trans-differentiation protocol with retinoic acid (RA), sonic hedgehog (SHH), and
neurotrophic factors were developed. With this protocol hADSCs could be converted into electrophysiologically active
motoneuron-like cells (hADSC-MNs), which expressed both a cohort of pan neuronal markers and motor neuron
speciﬁc markers. Moreover, after being primed for neuronal differentiation with RA/SHH, hADSCs were transplanted
into SCI mouse model and they survived, migrated, and integrated into injured site and led to partial functional
recovery of SCI mice. When ablating the transplanted hADSC-MNs harboring HSV-TK-mCherry overexpression system
with antivirial Ganciclovir (GCV), functional relapse was detected by motor-evoked potential (MEP) and BMS assays,
implying that transplanted hADSC-MNs participated in rebuilding the neural circuits, which was further conﬁrmed by
retrograde neuronal tracing system (WGA). GFP-labeled hADSC-MNs were subjected to whole-cell patch-clamp
recording in acute spinal cord slice preparation and both action potentials and synaptic activities were recorded,
which further conﬁrmed that those pre-conditioned hADSCs indeed became functionally active neurons in vivo. As
well, transplanted hADSC-MNs largely prevented the formation of injury-induced cavities and exerted obvious
immune-suppression effect as revealed by preventing astrocyte reactivation and favoring the secretion of a spectrum
of anti-inﬂammatory cytokines and chemokines. Our work suggests that hADSCs can be readily transformed into MNs
in vitro, and stay viable in spinal cord of the SCI mouse and exert multi-therapeutic effects by rebuilding the broken
circuitry and optimizing the microenvironment through immunosuppression.
Introduction
Spinal cord injury (SCI) is a devastating condition and
often results in life-long consequences such as paralysis
and associated complications1. A cascade of secondary
events follow the initial traumatic injury, characterized by
ischemia, hemorrhage, edema, inﬂammation, cell death,
and further tissue damage, and eventually result in neuron
demyelination, axonal degeneration, and cavitation at the
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injury site2–5. Existing treatments, include surgery and
antibodies against myelin-associated neurite growth
inhibitor6 and neurotrophic factor protection7,8, aiming to
stabilize the injury and prevent secondary complications.
However, these strategies have limited therapeutic bene-
ﬁts presumably due to their reliance on the adult body’s
limited self-repairing capacity to recover and rebuild the
disrupted neuronal network.
Stem cell therapy, as an alternative strategy, holds great
promise for spinal cord injury treatment for the ability of
stem cells to self-renew, to differentiate into multiple
lineages9,10, to secrete neurotrophic factors8,11,12 and anti-
inﬂammatory cytokines13–17. Several stem cell-based
strategies have been tested in experimental and clinical
settings for therapeutic effects in SCI therapy but with
variable hurdles14–16,18–21.
Mesenchymal stem cells (MSCs) are a group of het-
erogeneous multipotent adult stem cells22,23 can be dif-
ferentiated into chondrocytes24,25, adipocytes26,
myocytes27,28, endothelial cells29,30, and neurons31–34. The
main advantages of adipose-derived stem cells (ADSCs),
include the feasibility of autologous transplantation, the
ability to secrete neurotrophic factors and cytokines to
promote the survival of endogenous cells, and suppress
the inﬂammatory response to facilitate tissue repair17,35,36.
Among various MSCs, ADSCs take many advantages
over bone marrow stem cells, such as easier to harvest,
low senescence, and rich in tissue37. ADSCs may be pre-
programmed to differentiate toward a neural lineage38,
which has been conﬁrmed by several reports39–44. ADSCs
are also capable of supporting oligodendrocytes in vivo45
and transforming into functional Schwann cells46–50.
Since loss of motoneurons is a main cause of permanent
disability in SCI patients, it is expected that replacement
of motoneurons and/or prevention of secondary compli-
cations to the remaining motoneurons may lead to some
functional recovery. Mouse and human ESC-derived
motoneurons transplanted into animal models of SCI
could survive and integrate into the lesion site with sig-
niﬁcant recovery of motor function51,52. Recently, two
research groups independently reported the induction of
hADSCs into motoneuron-like cells40,53, using a protocol
modiﬁed from that used to convert ESCs/iPSCs into
motoneurons54,55. However, the therapeutic potential of
hADSC-derived motor neuronal cells has yet to be
established in a clinic relevant SCI model. This study for
the ﬁrst time optimized a stepwise protocol for high
efﬁcient ADSC-motoneuron trans-differentiation and
further investigated the therapeutic potential of hADSCs-
MN for SCI. We proved that pretreated hADSCs could
survive, integrate and become electrophyisiologically
active neuronal cells in injured spinal cord and participate
in re-establishing the broken neural circuits through a
relay fashion as well as optimizing the microenvironment
by immune-suppression, which eventually led to func-
tional recovery in locomotor.
Results
Differentiation of hADSCs into electrophysiologically
active motoneuron-like cells in vitro
The experimental diagram is shown in Fig. 1a. The
characterization of hADSCs was shown in Supplementary
Fig. 1. SHH and RA are important for neuralization and
ventralization of ESCs and iPSCs during neuron devel-
opment56–58. Thus, we attempted to treat hADSCs with
SHH and RA to initiate their differentiation toward
motoneurons (Fig. 1b–d). Before induction, the hADSCs
had only weak expression of neuronal marker MAP2 as
well as the motoneuron marker HB9 without expression
of any other neuronal progenitor markers of Olig2, Sox1,
mature motor neuron markers of NeuN, ChAT, and Islet
(Fig. 1b and Supplementary Fig. 2A). As early as 6 h after
induction, morphological changes became noticeable.
Afterward, hADSCs gradually became polarized and
formed neurite-like structures. By day 3, hADSCs had
already expressed various neuronal progenitor markers,
such as GFAP, Sox1, Olig2, as well as motoneuron mar-
kers of NeuN, Synapsin1/2, Islet, HB9, and ChAT (Fig. 1c
and Supplementary Fig. 2B). Most of these differentiated
cells were structurally simple and usually bi-polarized,
and the expression of MAP2, ChAT, and Synapsin1/2 was
mainly concentrated within soma implying that they were
likely just turning into immature neurons/motoneurons
without synaptic structures (Supplementary Fig. 2B).
Neurotrophic factors were supplemented to further
accelerate the maturation of these nascent motoneuron-
like cells for another 3–6 days. By day 6, complex den-
dritic structures with secondary or tertiary branches as
well as puncta-like synapses were easily detectible. The
expression of mature neuronal markers, such as MAP2,
NF-200, NeuN, Synapsin1/2, and NF-200; as well as
motoneuron markers HB9, ChAT, and Islet were sig-
niﬁcantly augmented (Fig. 1d and Supplementary Fig. 2C).
On the contrary, the expression of progenitor markers
such as Olig2, Sox1, and GFAP decreased dramatically
(Fig. 1d, e, Supplementary Fig. 2C), indicating that the
majority of the hADSCs were converted into relatively
mature neurons/motoneurons with high purity by the
protocols we developed (Fig. 1e).
To check whether hADSC-MNs could obtain action
potential, whole-cell patch-clamp recordings were done
after 6-day induction. In the whole-cell voltage-clamp
conﬁguration, voltage-dependent inward currents were
recorded from hADSC-MNs (Fig. 1f). When 1 µM TTX
was added, these inward currents were completely
blocked, indicating that these inward currents were typi-
cal voltage-gated sodium currents (Fig. 1f). To verify these
ﬁndings, qRT-PCR data demonstrated that voltage-
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dependent sodium, potassium, and calcium channels were
expressed in these motoneuronal-like cells. (Fig. 1g).
Some lineage-speciﬁc markers such GAP43, an inter-
neuronal marker, and GFAP, a neural stem cell or glial
marker, were detectable (Fig. 1g). The expression level of
motoneuronal and synaptic marker genes, such as SIM1,
OLIG2, HB9, CHAT, NKX6.1, NF-200, and SNAP25,
were all upregulated (Fig. 1h, i). Taken together, our step-
wise protocol could transdifferentiate hADSCs to elec-
trophysiologically functional neurons.
Therapeutic effects of the transplanted hADSC-MNs in the
SCI mouse model
Whether hADSC-MNs could exert therapeutic effects
in vivo in a rodent SCI model was unknown. The sche-
matic experimental plan was as shown in Supplementary
Fig. 3A. A T8 crushed SCI mouse model was developed59
was shown in Supplementary Fig. 3B, C. Transplanted
hADSC-MNs successfully decreased injury cavity as
shown in Supplementary Fig. 3D. Basso, Beattie,
Bresnahan-derived Basso Mouse Scale (BMS) locomotor
rating scale scores in total (Supplementary Fig. 3E),
including the primary score and subscore, were applied
and processed (Fig. 2a, b). The scores of the phosphate-
buffered saline (PBS) control group increased gradually
and reached a plateau around 3 weeks and last until the
end of the observation after the injury, while hADSC-MN
group increased steadily and continuously up to 5 weeks
before reaching a plateau which was signiﬁcantly higher
than those achieved by the PBS control group (P < 0.001).
The transplanted hADSC-MNs appeared to exert a
positive-therapeutic effect as early as 1-week post-trans-
plantation (P < 0.05) (Fig. 2a, b). These data demonstrate
that hADSC-MN transplantation can signiﬁcantly ame-
liorate the histopathological, behavioral, and functional
deﬁcits generated in this SCI mouse model.
The survival and integration of transplanted hADSC-MN
into the injured spinal cord
Next, we performed immunohistochemical staining to
determine the fate of the transplanted cells. As expected,
no GFP-positive cells were detected in the PBS control
group. The injury site remained visible with obvious cavity
(Supplementary Fig. 3D, F, and G). In contrast, a large
number of GFP-positive cells were observed in the
hADSC-MN transplanted group, mostly in the center of
the injury site and the rostral and caudal surrounding
areas bilaterally (Fig. 2c, d). The GFP-positive cells were
predominantly (>80%) MAP2-positive but occasionally
GFAP positive (<10%), suggesting that the transplanted
hADSC-MN mainly differentiated toward a neuronal
lineage in vivo (Fig. 2e–i). Furthermore, the precondi-
tioned hADSCs adopted a multipolarized morphology
in vivo resembling mature neurons, appeared to integrate
with the host tissue and migrated out for at least several
millimeters from the site of injection (Fig. 2c, d, enlarged
1–3 and a–c). The enlarged showed the caudal part away
from the injury center. The sizes of the cavities that
formed after injury were signiﬁcantly smaller in the
transplanted group compared to the control group (Fig. 2j).
Most importantly, it is intriguing to explore whether the
transplanted cells can integrate into the injured site of
spinal cord and become electrophysiologically functional.
Indeed, GFP-labeled hADSC-MNs were subjected to the
whole-cell patch-clamp recording from acutely prepared
slices of the injured spinal cord and demonstrated the
capacity of ﬁring action potential and receiving sponta-
neous synaptic inputs (Fig. 2k–o), which further demon-
strates the long-term viability, success of neural
conversion and functional integration of the transplanted
human cells into the host spinal cord tissue.
The transplanted hADSC-MNs directly participate in re-
establishing the broken neural circuitry in injured site
To check whether the introduced hADSC-MNs can
functionally integrate into the neuronal circuitry, HSV-
TK-mCherry-Ganciclovir (GCV) cell suicide system was
applied60. The BMS scoring data indicated that after
8 days of continuous GCV injection per day, the BMS
score gradually but signiﬁcantly decreased, implying the
functional relapse of the mobility capacity of injured mice
(Fig. 3d). Before the administration of GCV, the mCherry-
labeled hADSC-MNs were easily detectible at the injured
site and could be co-stained by neuronal marker MAP2
(Fig. 3a). After GCV injection, the mcherry-positive cells
sharply decreased compared with the non-GCV injected
(see ﬁgure on previous page)
Fig. 1 Differentiation of hADSCs into motoneuron-like cells by a step-wise protocol a Schematic ﬂow chart for in vitro differentiation of
hADSCs into motoneuron-like cells. b Before induction, hADSCs have little expression of neuronal or motoneuron markers such as NeuN, HB9, ChAT,
except to low expression of MAP2. c After 3 day induction with Purmorphamine(or SHH) and RA, hADSCs start to express high level of neuron/
motoneuron markers MAP2, NeuN, HB9, ChAT, as well as motoneuron progenitor marker Sox1. d Another 3 days’ induction supplemented with
neurotrophic factors further boosts the maturation of the hADSC-derived motor neuron-like cells with the high-level expression of neuron/
motoneuron markers MAP2, NeuN, NF-200, Synapsin1/2, Islet, HB9, and ChAT. The neurites of the differentiated cells become more complex.
e Quantiﬁcation of immunostaining for various markers at different stages. f Sodium currents can be recorded at Day 6 with whole-cell patch-clamp,
which can be blocked by 1 µM TTX. g The expression of various neuronal marker genes, including sodium, potassium, and calcium channels is
elevated after 6 days’ induction by qRT-PCR. h, i The augmented expression of some motoneuron speciﬁc genes expression is veriﬁed by qRT-PCR.
Scale bar:100 µm. Statistics is done by two-way ANOVA of Graphpad Prism 5
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counterpart (Fig. 3b, c). Western blotting data demon-
strated the human speciﬁc nuclear antigen was expressed in
the hADSC-MN transplanted group (SCI-hADSC-MN)
and expressed neither in the group of SCI-Sham nor the
group of SCI-PBS, implicating the long-lasting existence of
transplanted human cells in vivo (Fig. 3e, f). We further
performed the in vivo electrophysiological experiment to
test the integrity of the cerebrospinal neural circuits under
various conditions. The motor-evoked potentials (MEP)
were elicited in the frontal cerebral cortex and recorded in
the skeletal muscle of hind limb of the mice. MEPs could be
steadily recorded before the surgical interference (Fig. 3g,
inset a). After establishing the SCI model, the MEP could be
barely recorded which could be restored by hADSC-MN
transplantation (Fig. 3g, inset b and c). After GCV admin-
istration, the MEPs were largely abolished again (Fig. 3g,
inset d and e), indicating the essential role of transplanted
cell in ensuring the conduction of electric signals. Alto-
gether, these data demonstrated that the transplanted
hADSC-MNs survived, integrated, and directly participated
in rebuilding the disrupted neural circuitry in SCI model.
To determine how the transplanted hADSC-MNs estab-
lished the synaptic connection with endogenous neurons,
retrograde neuron tracing with wheat-germ agglutinin
(WGA) was carried out61. Signiﬁcantly, higher expression
of WGA was observed at the center of the injured site as
well as the caudal part adjacent to the injured site, implying
the re-establishment of the synaptic connections across the
injured site of the spinal cord (Fig. 4a–d). WGA had been
detected in large amount of transplanted hADSC-MNs as
indicated by co-localization of GFP with WGA (Fig. 4b,
inset b), suggesting that endogenous neurons directly
innervate the transplanted cells with synapses.
Immunosuppressive effect of transplanted hADSC-MNs at
the injured site of spinal cord in SCI mice
It is intriguing to test whether hADSC-MNs can exert
immune modulatory effects at the injured site. As
expected, SCI led to a massive inﬂammatory response
with glial activation as indicated by numerous GFAP+
cells present and persisting in and around the injury site
(Fig. 5a). This peri-lesional reactive gliosis was vastly
reduced (Fig. 5b) in the hADSC-MN treated group,
strongly suggesting that the transplanted hADSC-MN had
a suppressive effect on the injury-induced inﬂammatory
response. The immune factor proﬁling for both blood
serum and the spinal cord lysate samples at 7 days after
hADSC-MNs transplantation showed that the spinal cord
injury caused a global inﬂammatory response as revealed
by signiﬁcantly increased level of pro-inﬂammatory fac-
tors, such as IL1α, MCP-1, RANTES, INF-γ, etc., both in
the blood serum and cell lysates from the injured sites
(Fig. 5c–e). However, the transplanted hADSC-MNs eli-
cited a focal immunosuppressive effect at the injury site
by upregulating the expression of a spectrum of anti-
inﬂammatory factors, including IL-5, IL-9, IL-10, IL-13,
etc. This effect is relatively restricted to the site where the
transplantation was implemented since the immune fac-
tors in the serum did not change much by hADSC-MN
transplantation.
Discussion
Despite major advances in the medical and surgical care
of SCI patients, so far no effective treatments have
emerged to ameliorate the complications for severe
SCI5,62. Stem cell-based therapy has the potential to tackle
almost all the problems encountered in SCI, including
loss of neurons and schwann cells, axonal degeneration
and demyelination, disrupted vascular structures, and
chronic inﬂammation62–66, and is an emerging approach
with high potential for translation to the clinic. To date,
various types of stem cells have been tested with variable
recovery of function reported20,67–69. hADSCs are now
increasingly considered the optimal choice of stem cells
for various therapeutic applications due to their easy
access, self-renewal ability, multipotency, free of immu-
nogenicity70,71. In addition, in vitro neuronal differentia-
tion of ADSCs has been reported by several research
(see ﬁgure on previous page)
Fig. 2 Transplanted hADSCs survive, integrate, and differentiate into functional neurons at the injured spinal cord in SCI mouse models.
a, b Transplantation of preconditioned hADSCs promotes the recovery of locomotor capacity of SCI mice as evaluated by the BMS scoring (both
primary and subscore, n= 12) at different time points. c Immunostaining of spinal cord slices from SCI mice with the astrocyte marker GFAP 8 weeks
after hADSC transplantation. Representative images from the rostral, central, and caudal part of the injury site are shown in enlargements a–c as well
as further enlargement 1–3, respectively. d Immunostaining of spinal cord slices from SCI mice with the neuronal marker MAP2 8 weeks after hADSC
transplantation. Representative images from the rostral, central, and caudal part of the injury site are shown in enlargements a–c, respectively; scale
bar: 400 and 50 μm (for the enlarged pictures). e–g Statistics for the ratio of GFAP positive astrocytes out of the total cell count, GFP-positive
transplanted cells out of the total cell count and the GFAP-positive astrocytes derived from GFP-positive transplanted cells respectively, at various
sites (n= 5). h, i Statistics for the ratio of MAP2-positive neurons out of the total cell count, MAP2-positive neurons out of the total transplanted cells
(n= 5); j the area of cavitation at the injury site was calculated with Image-Pro Plus software (n= 12). Quantiﬁcation was performed by counting at
least ﬁve ﬁelds per sample for each slice and analyzed by student t test; k–o patch-clamp whole-cell recording is performed on the GFP-labeled
hADSC-derived neuron-like cells in the acutely prepared spinal cord slice from SCI mice. k, l Representative bright ﬁeld image of a patched cell with
ﬂuorescence illumination;m a representative trace shows that the good seal (GΩ) can be achieved; n, o the representative traces of action potentials
and spontaneous synaptic currents, respectively, recorded from transplanted GFP-positive hADSCs
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groups12,49,72 and the potential application of ADSCs for
cell replacement therapy of various neurological diseases
including SCI has been highlighted. ADSCs also have the
immune modulatory capacity to reduce inﬂammatory
response and improve the microenvironment73–75 to
promote the survival of both the transplanted and the
endogenous cells.
Transplantation of mouse/human ESC-derived moto-
neurons in a mouse model of SCI has been reported to
lead to improved locomotor function67,76–78. To date,
little is known about hADSCs’ capacity for motoneuron
differentiation in vitro40,53. No data are available on the
potential for hADSC-derived motoneuron for spinal cord
injury in vivo. Ideally, hADSC-MNs may take theoretical
advantages over undifferentiated hADSCs in cell repla-
cement for treating SCI. In the present study, we devel-
oped a robust protocol for isolated high pure hADSCs
consistent with previous reports12,49,72. These hADSCs
expressed most of the embryonic stem cell markers,
including SOX2, OCT4, c-MYC, and NANOG70, but at
lower levels compared with ESCs, might confer hADSCs
the self-renewal capacity and multipotency alongside with
low-tumorigenic potential. It is of critical importance to
evaluate the tumorigenic potential of hADSCs, especially
after multiple passages. In the present study, no tumor-
igenesis was detected 6 months after hADSC-MN trans-
plantation. The isolated hADSCs were then induced into
motoneuron-like cells in a stepwise protocol using SHH
and RA initially to promote neuralization and ventralisa-
tion of ESCs70,79,80. Upregulated expression of moto-
neuron speciﬁc markers Sox1, OLIG2, Islet, HB9, and
ChAT, and general neuronal markers MAP2, NeuN,
SYNAPSIN1/2, and NF-200 suggest that these cells con-
sisted of a mixture of progenitor cells and motoneurons.
Further conditioning with neurotrophic factors BDNF,
GDNF, and IGF-1 for 3 days promoted the maturation of
hADSC-MNs56,79. The expression of the MN progenitor
marker of OLIG2 diminished and SYNAPSIN assumed a
punctate distribution, suggesting the formation of
synaptic structures and thus an increase in the maturation
of terminally differentiated MNs. These MN-like cells
eventually became electrophysiologically active, but
remain immature with very high input resistance and
depolarized resting membrane potentials. These cells may
be still in an intermediate stage of maturation considering
that differentiation of human ESCs into functionally
mature motoneurons normally takes more than 6 weeks
in vitro81. Actually before induction, there was weakly
detectable expression of several neuronal differentiation
marker genes, including MAP2, Sim-1, Olig2, NKX6.1,
and NF-200 observed in our study. Taken together,
these data have demonstrated the feasibility of differ-
entiating hADSCs into cells with neuron/motoneuron
characteristics.
It is noteworthy that hADSC-MNs survived in WT
mouse spinal cord for at least several months, strongly
indicating that hADSCs and their differentiated progeni-
tors might be immune privileged cells as is the case for
other MSCs82. Therefore, it is interesting to know whe-
ther ADSCs share similar immune properties, MHC I
positive, MHC II negative, and lacking the co-stimulatory
molecules CD40, CD80, and CD8683. Another important
property of hADSCs is that these transplanted cells exert
an anti-inﬂammatory effect as demonstrated by their
ability to inhibit gliosis as well as the spinal cord immune
cytokine proﬁling variance. The immune factor proﬁling
pattern demonstrated that these hADSC-MNs could
dramatically drive the tissue speciﬁc macrophage to
transform from M1 type to M2 type, which may result
from the accelerated IL-13 expression. Also, the trans-
plantation of hADSC-MNs stimulates IL-9 expression in
the spinal cord lysates. IL-9, through the interleukin-9
receptor (IL9R), activates different signal transducer and
activator proteins and thus connects this cytokine to
various biological processes such as stimulating cell pro-
liferation and prevents apoptosis, inhibit TNF-α release84.
The upregulation of IL-9 in spinal cord lysates of SCI-
hADSC-MN group of mice compared with the SCI-PBS
group of mice implied good survival of implanted
hADSC-MNs and promotion of endogenous neuronal
cells. MCP-1, also known as CCL2, recruits monocytes,
memory T cells, and dendritic cells to the sites of
inﬂammation produced by either tissue injury or patho-
gen infection85. Higher expression of MCP-1 in the spinal
(see ﬁgure on previous page)
Fig. 3 The transplanted hADSCs can participate in reconstitution of the broken circuitry and lead to the behavioral recovery of the SCI
mice. a Immunostaining images demonstrate hADSCs are effectively infected by HSV-TK-mCherry-GCV viruses and become neuronal-like cells and
integrate into the injured site of SCI spinal cord, as stained positively by MAP2 and vGLUT. b Administration of GCV can eliminate most of the
transplanted cells as demonstrated by co-staining of mCherry with NeuN, MAP2, and GFAP. c Statistic analysis shows both mCherry-positive cells and
mCherry-positive neurons are largely deleted by GCV administration within 2 weeks (n= 5); d BMS scoring in total demonstrate that GCV
administration leads to gradual worsening of locomotor capacity and functional relapse (n= 12); eWestern blotting data show positive expression of
HuNA in the SCI-hADSC-MN group, further demonstrating the long-term survival of transplanted cells; f Western blotting quantiﬁcation data is
analyzed by two-way ANOVA; g motor-evoked potential is analyzed among different groups to test the integrity of the neural circuitry along the
corticospinal axis, showing that the transplanted hADSCs are essential for the re-establishment of neural circuitry in SCI mice and deletion of
transplanted cells by GCV will lead to the disruption of the neural circuitry again (n= 12). Scale bar: 25 μm
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Fig. 4 Functional rebuilding of neuronal circuitry by transplanted hADSCs in SCI mice as revealed by retrograde tracing marker WGA. The
data show the immunostaining with WGA and NeuN antibodies in the spinal cord slices from various groups. a The negative PBS control group;
b the hADSCs transplanted group; c the Sham group; in each group, double staining of WGA and NeuN are performed and representative images from
central, rostral, and caudal part around the injured site are shown, demonstrating the morphological and functional integration of hADSC-MN into the
host spinal cord tissue; d statistics of the WGA-, NeuN-, and DAPI-positive ratio from each site for various groups of mice (n= 5), Scale bar: 100 μm
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cord lysates of the SCI-hADSC-MN than SCI-PBS mice
meant the transplanted hADSC-MNs could recruit
inﬂammatory cells to the injured spinal cord and parti-
cipate the SCI repair, and meanwhile, promote the anti-
inﬂammatory factor expression of IL-5, IL-10, and IL-13.
The immunosuppression of MSCs has been reported to
result from the concerted action of chemokines, such as
INF, TNF-α, and IL-1 with nitric oxide74,75,86,87. Pro-
inﬂammation factors, including IFN-γ, MCP-1, RANTES,
IL-1β, and anti-inﬂammatory factors, such as IL-10 and
IL-13 were relatively higher in the spinal cord lysates of
SCI-hADSC-MNs than the SCI-PBS groups. In addition,
hADSCs have the ability to secrete various factors,
including HGF, VEGF, TGF-β, IGF-1, interleukins, adi-
ponectin, angiotensin, cathepsin D, pentraxin, pregnancy
zone protein, retinol-binding protein, and CXCL1288,89,
which can potentially inhibit apoptosis, promote vascular
reconstitution, minimize inﬂammation and optimize the
microenvironment at the injury site.
Evidence is needed for whether the therapeutic effect
results from the replacement of degenerative cells by
hADSC-MNs. Therefore, it is important to determine
whether a functional relapse could happen if the trans-
planted cells are eliminated after stable recovery is
established. Function relapse both from hindlimp loco-
motor behavior and muscle electrical potential were
found on the HSV-TK-mCherry-hADSC-MN trans-
planted mice after i.p. injection of ganciclovir. In addition,
analysis of the subtype fate of hADSC-MN is also crucial
to clarify the therapeutic mechanism. It is likely that in the
in vivo conditions, the terminally differentiated cells
consist of motoneurons as well as other types of neurons,
such as glutamatergic and GABAergic neurons, which
synergistically help to rebuild the local circuitry and allow
the electrical signals to be conducted through the injured
site90, this could be supported by the histoimmunostain-
ing of the spinal cord slices with vGLUT antibodies.
Morphologically, the transplanted neurons appeared
relatively mature with complex neuritis, which had been
further conﬁrmed by determining their indeed ﬁring
action potentials and producing synapse current, implying
their synaptic formation with endogenous neuronal cells.
On the other hand, the WGA tracing system data also
provided strong evidence for neuronal relay formation
between the transplanted hADSC-MNs and the endo-
genous neurons.
This study demonstrated that hADSCs could be trans-
differentiated into electrophysiological functional
hADSC-MNs expressing motoneuron markers. After
being transplanted into the mouse injured spinal cord,
signiﬁcant behavioral recovery was observed. These
hADSC-MNs were immune privileged and survived over
8 week. The majority of these hADSCs became neurons
and likely participated in rebuilding the damaged circuitry
at the site of spinal cord injury by relay mode and opti-
mizing the microenvironment by modulating the post-
injury inﬂammatory response (Fig. 6). Our study not only
has provided relative simple strategies to guide the motor
neuron differentiation of ADSCs both in vitro and in vivo,
has also shown promising therapeutic efﬁcacy of hADSC-
MNs in a rodent SCI model.
Materials and methods
Differentiation of hADSCs into motoneuron-like cells
hADSCs were washed with PBS at P3 and switched to the
serum free motoneuron induction DMEM/F12 medium
with the addition of 1 μM purmorphamine or 10 ng/mL
SHH and 0.1 μMRA (all trans-retinoic acid)91. The detailed
protocol referred to the Supplemental information.
Clinic-relevant mouse SCI compression model
Six- to eight-week-old C57/BL6 mice were housed in a
controlled SPF level environment (12 h light/dark cycling
at 21 °C) with free access to water and standard chow diet.
The crushing protocol referred to the Supplemental
information59.
hADSC labeling, motoneuron induction, and transplantation
hADSCs were infected with EGFP-expressing lentivirus
FG12 were subjected motoneuron induction, transplan-
tation as the detailed protocol described in the Supple-
mental information.
(see ﬁgure on previous page)
Fig. 5 Transplanted hADSC-MNs exert suppressive effect on the inﬂammatory response in SCI mouse models. a In the injury site, striking glial
activation was present in the PBS control group as revealed by high expression of GFAP. Scale bar: 250 and 50 μm (for A 1–3). b In the hADSC-MN
transplanted group, GFAP expression was signiﬁcantly attenuated by the presence of GFP-positive transplanted cells, demonstrating their anti-
inﬂammatory effects. Scale bar: 250 and 50 μm (for B 1–3). c–e Immunocytokine secretion proﬁling in both spinal cord lysates and blood serum is
analyzed in various groups; c the cytokine proﬁling in the spinal cord lysates; d the cytokine proﬁling in the blood serum; SCI mice injected with PBS
or hADSC-MN 7 days after surgery and collected spinal cord lysate supernatant 7 days after injection was grouped as SCI-7D-7D-PBS and SCI-7D-7D-
hADSC-MN, respectively, and the scramble group labeled as SCI-Sham. The experimental protocol strictly follows the MCYTOMAG-70K-PX32 (Merk
Millipore, Lot#2618731); e the variation of cytokine proﬁling correlated with the corresponding macrophage and pro- or anti-inﬂammation factors
changes; Scale bar: 100 μm
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Electrophysiological recording for hADSC-MNs both
in vitro and in vivo
To characterize the hADSC-MNs, whole-cell patch-clamp
recording was used to assess their electrophysiological
activity. The protocols used were as previously
described92–94. The detailed protocol referred to the Sup-
plemental information.
Behavioral and histological analysis
Functional tests were performed and analyzed by two
examiners blinded to the treatment groups. These tests
were performed immediately after the SCI surgery, every
3–4 days for the ﬁrst 2 weeks after cell transplantation and
then weekly for the rest of the 8 weeks. Locomotor func-
tion was evaluated using the BMS locomotor rating scale95.
At the end of 8 weeks, the spinal cord was collected, ﬁxed,
postﬁxed, dehydrated with sucrose, embedded by OCT gel
(Sakura Finetechnical), and stored at −80 °C until sec-
tioning. Slices were set as 20 μm and immunohistological
staining was carried out as previously described76.
HSV-TK-mCherry-GCV cell ablation system construct and
application
HSV-TK-mCherry packaging system was donated by
Prof. Zhang Hongsheng. This system was ﬁrstly used to
infect the in vitro hADSCs to determine the GCV amount
for in vivo i.p injection. Six weeks after HSV-TK-
mCherry-hADSC-MN transplantation, the transplanted
SCI mice received an 7-day i.p injection of GCV at
100 ng/kg body weight per day in order to let the intro-
duced cells commit suicide96. The BMS scoring and MEP
were performed before and after GCV injection in each
group97,98. The detailed protocol referred to the Supple-
mental information.
Tracing of hADSC-MNs in SCI mice by histoimmunostaining,
retrograde neuron tracing manners of WGA
Two weeks before the mice were sacriﬁced for his-
toimmunostaining or histochemistry analysis, WGA
overexpressing lentivirus (5 µL at 109/mL, the construc-
tion data of Lentivirus-WGA refer to Supplementary
Fig. 4) were injected into the somatosensory area through
a glass micropipette and stereotaxic injector (KDS310,
Muromachi-Kikai).
Immune modulation of hADSC-MNs on spinal cord of SCI
mice
To check whether the introduced hADSC-MNs play any
immune modulatory roles, 32 inﬂammation or immune
related factors were set in one 96-well panel named mouse
cytokine/chemokine magnetic bead panel. The protocols
strictly followed the kit (MCYTOMAG-70K-PX32,
Lot#2618731) instructions. The experiment performance
service was professionally provided by Merck Millipore.
Statistical analyses
All data are expressed as mean ± SD or SEM. The sta-
tistical signiﬁcance was determined using one-way or two-
way ANOVA Bonferroni post-tests between groups by
GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego, CA, USA, www.graphpad.com.
P < 0.05 was considered statistically signiﬁcant.
Fig. 6 Transplanted hADSC-MNs exert their therapeutic effects through rebuilding neural circuit, immune/inﬂammatory modulation, and probable
promoting endogenous neuron regeneration and in SCI mouse models
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